Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04890093CT.gov Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors | — | Suspended | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rhabdomyosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Locnartecan (this asset) | National Cancer Institute (NCI) | P1/2 | CC · 43 |
| Ipilimumab | Children's National Research Institute | P2 | BB |
| Irinotecan | Milton S. Hershey Medical Center | P2 | BB |
| Calcium Phosphate | Children's Oncology Group | P3 | BB |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
| Adriamycin | Children's National Research Institute | P2 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | B |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | B |
| Dactinomycin | Children's Oncology Group | P3 | B |
+42 more in the Rhabdomyosarcoma cohort
Other indications for Locnartecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ewing Sarcoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Locnartecan in Rhabdomyosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hsp90-targeted-sn-38-conjugate-pen-866-rhabdomyosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →